DOCSLIB.ORG

Aqueous Humor Flow in Normal Human Eyes Treated with Brimonidine and Dorzolamide, Alone and in Combination

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Aqueous Humor Flow in Normal Human Eyes Treated with Brimonidine and Dorzolamide, Alone and in Combination CLINICAL SCIENCES Aqueous Humor Flow in Normal Human Eyes Treated With Brimonidine and Dorzolamide, Alone and in Combination Hidetoshi Tsukamoto, MD; Lill-Inger Larsson, MD, PhD Objectives: To measure the effectiveness of topical 0.2% 28.2%±18.0% (PϽ.001), dorzolamide by 19.3%±22.0% brimonidine tartrate as a suppressor of aqueous humor (P=.007), and the combination of brimonidine and dor- flow in the human eye compared with the effectiveness zolamide by 37.2%±20.6% (PϽ.001). The combination of 2% dorzolamide hydrochloride, and to measure the of both drugs statistically significantly suppressed aque- additivity of the effects of the 2 drugs. ous humor flow compared with dorzolamide alone (PϽ.001) and brimonidine alone (P=.04). The IOP was Design: A randomized, double-masked, placebo- reduced by a mean±SD of 11.6%±10.1% (PϽ.001) by controlled study was performed in 20 healthy human sub- brimonidine, 8.5%±14.1% (P=.02) by dorzolamide, and jects. The topical drugs were instilled twice daily the day 17.9%±16.5% (PϽ.001) by the combination. The com- before and again in the morning on the day of the mea- bination of drugs reduced IOP better than dorzolamide surements. The rate of aqueous humor flow was mea- (PϽ.001), but not more than brimonidine (P=.06). sured from 8 AM to 4 PM by clearance of topically ap- plied fluorescein using a fluorophotometer, after Conclusions: The combination of brimonidine and dor- administration of doses of each drug singly and both drugs zolamide caused a further reduction of aqueous humor flow together. Intraocular pressure (IOP) was measured with compared with each drug applied alone. The IOP was fur- applanation tonometry. ther reduced by the combination compared with dorzol- amide alone, but not compared with brimonidine alone. Results: Compared with placebo, brimonidine re- duced the aqueous humor flow by a mean±SD of Arch Ophthalmol. 2004;122:190-193 ␣ HE ADRENERGIC 2-RECEP- cause there are many ocular hypotensive tor agonist brimonidine tar- drugs commercially available, different trate1-7 is a topically ap- therapeutic regimens exist. Brimonidine plied ocular hypotensive added to treatment with ␤-adrenergic an- agent. Studies of brimon- tagonists has been shown to lead to a sig- idine have demonstrated that the ocular nificant additive lowering of the IOP and T 24 hypotensive effect primarily is caused by of the aqueous humor production. Bri- reduction of aqueous humor produc- monidine and dorzolamide are used in tion,7-15 but increased uveoscleral out- clinical practice not only as monothera- flow has also been reported in rabbits16 and pies but also in different combination treat- in humans.11 ments.12-15,25-29 The purpose of the pres- Dorzolamide hydrochloride is a car- ent study was to measure aqueous humor bonic anhydrase inhibitor that is used for flow and IOP after topical administration treatment of glaucoma. This topically ap- of brimonidine, alone and in combina- plied drug lowers the intraocular pres- tion with dorzolamide, to determine sure (IOP) by suppressing the aqueous hu- whether the effects of the 2 drugs are ad- mor production.17-23 Compared with a ditive on aqueous flow and IOP. systemically administered drug of the same class, it has fewer systemic adverse ef- METHODS fects, but its ability to reduce the aque- From the Department of 17,20 The study was carried out at the Department Ophthalmology, Uppsala ous humor formation is weaker. of Ophthalmology, Uppsala University Hospi- University Hospital, Uppsala, Monotherapy is not always suffi- tal. Twenty healthy volunteers were enrolled Sweden. The authors have no cient for an adequate control of the IOP into the study. There were 10 women and 10 relevant financial interest in in patients with glaucoma, and addi- men (mean age, 29.2 years; range, 24-49 years). this article. tional treatment may be prescribed. Be- All subjects underwent an eligibility examina- (REPRINTED) ARCH OPHTHALMOL / VOL 122, FEB 2004 WWW.ARCHOPHTHALMOL.COM 190 ©2004 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/30/2021 Table 1. Aqueous Humor Flow From 8 AM to 4 PM* % Difference (P Value) Aqueous Humor Flow, vs Dorzolamide vs Brimonidine Drug Applied No. of Eyes µL/min vs Placebo Hydrochloride Tartrate Placebo 20 3.04 ± 0.86 . Dorzolamide 20 2.45 ± 0.56 19.3 ± 22.0 (.007) . Brimonidine 20 2.18 ± 0.54 28.2 ± 18.0 (Ͻ.001) 11.0 ± 20.5 (Ͻ.09) . Brimonidine and dorzolamide 20 1.91 ± 0.50 37.2 ± 20.6 (Ͻ.001) 22.1 ± 18.7 (Ͻ.001) 12.5 ± 22.1 (.04) *Data are given as mean ± SD. tion consisting of a medical and ophthalmic history, visual acu- IOP was then recorded as the mean of the 3 measurements. Di- ity measurement, slitlamp examination, applanation tonom- lute milk rather than fluorescein was used as the disclosing agent etry, and ophthalmoscopy. Exclusion criteria were ocular disease, to avoid the introduction of more fluorescein to the cornea and systemic disease requiring long-term medical treatment, preg- mismeasurement of aqueous humor flow. nancy or lactation, inability to comply with tonometry or fluo- Aqueous humor flow was calculated from the clearance rophotometry, an IOP difference between the 2 eyes greater than of fluorescein at each 2-hour interval by using the following ⌬ ⌬ ⌬ 3 mm Hg, and known drug hypersensitivity. The research pro- equation: clearance= M/(Ca t), where M is the loss of mass tocol followed the tenets of the Declaration of Helsinki and was of fluorescein in the combined cornea and anterior chamber ⌬ approved by the Ethical Committee of Uppsala University. An during t interval, and Ca is the mean concentration in the an- informed consent was obtained from all participants. The study terior chamber during the interval, estimated from the initial consisted of 2 parts. At least 4 weeks elapsed between the parts and final fluorescence and assuming a single exponential de- to ensure complete elimination of the drugs. In part 1, the effect cay. Aqueous humor flow was calculated from the rate of clear- of 0.2% brimonidine–treated eyes vs placebo-treated eyes was ance of fluorescein after subtracting the presumed rate of dif- studied. In part 2, topical application of 2% dorzolamide was fusional clearance (0.25 µL/min).30 added to both eyes. Four treatment regimens were thus com- After completion of the study and tabulation of the data, the pared, with 20 eyes in each treatment group: (1) placebo- code was broken and the data stratified by drug. The statistical treated eyes, (2) brimonidine-treated eyes, (3) dorzolamide- analysis was carried out using a 2-sided t test for paired samples. treated eyes, and (4) brimonidine and dorzolamide–treated eyes. PϽ.05 was considered statistically significant. The coefficient of The study was randomized, double-masked, and placebo- variation of measurements of aqueous humor flow under condi- controlled. The brimonidine, dorzolamide, and placebo eye- tions similar to those in this experiment is approximately 23%.31 drops were given by random assignment and were adminis- The mean±SD aqueous humor flow in daytime is 2.75±0.63 µL/ tered from identical-appearing dropper bottles labeled by subject min.30 A sample size of 20 in each group provided a power of 95% number, sequence, and right and left eyes. These sterile eye- for detecting a true difference of 20% between the eyes.32 dropper bottles contained 0.2% brimonidine tartrate (Alpha- gan; Allergan, Inc, Irvine, Calif), 2% dorzolamide hydrochlo- RESULTS ride (Trusopt; Merck Sharp and Dohme/Isotopes, St Louis, Mo), or placebo (Isopto-Plain; Alcon Laboratories, Fort Worth, Tex). The effects of the different drugs on aqueous humor flow Each part of the study was performed on 2 sequential days, are presented in Table 1. Brimonidine reduced aque- day 1 and day 2. On day 1, the subjects reported to the re- Ͻ search area at 8 AM, and they were given 1 drop of 0.2% bri- ous humor flow by a mean±SD of 28.2%±18.0% (P .001) monidine in one eye and 1 drop of placebo in the other eye. and dorzolamide by 19.3%±22.0% (P=.007) compared The procedure was repeated at 5 PM. On day 2, when flow was with placebo, while there was no statistically significant measured, eyedrops were again instilled at 8 AM. As a precau- difference between brimonidine and dorzolamide (P=.09). tion to prevent cross-contamination between the eyes, sub- Brimonidine and dorzolamide applied in combination sup- jects were given separate tissues for each eye and were asked pressed the flow by a mean±SD of 37.2%±20.6% com- to blot only one eye with each tissue. In part 2, brimonidine pared with placebo (PϽ.001). The aqueous humor flow and placebo eyedrops were administered according to the same was statistically significantly reduced by the combina- schedule as in part 1, but at every time point for eyedrop in- tion of both drugs compared with dorzolamide alone stillation, 1 drop of 2% dorzolamide was also administered to Ͻ both eyes 5 minutes after the other eyedrops (ie, dorzolamide (P .001) and brimonidine alone (P=.04). was administered twice daily). The research personnel admin- The IOP (Table 2) was statistically significantly re- istered all eyedrops, except fluorescein, because of the risk of duced by a mean±SD of 11.6%±10.1% by brimonidine error with eyedrop self-administration. alone (PϽ.001) and 8.5%±14.1% by dorzolamide alone The subjects were instructed to awaken at 2 AM on day 2 (P=.02) compared with placebo, but there was no dif- and instill 1 drop of 2% fluorescein into each eye 3 to 5 times, ference between the effects of the 2 drugs in reducing IOP according to age, at 5-minute intervals, and then they returned (P=.35).
Load more

Recommended publications
  • WO 2014/066775 Al 1 May 2014 (01.05.2014) W P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/066775 Al 1 May 2014 (01.05.2014) W P O PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61F 9/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/US20 13/066834 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 25 October 2013 (25.10.201 3) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 61/719,144 26 October 2012 (26. 10.2012) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: FORSIGHT VISION5, INC. [US/US]; 191 kind of regional protection available): ARIPO (BW, GH, Jefferson Drive, Menlo Park, CA 94025 (US). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: RUBIN, Anne, Brody; 191 Jefferson Drive, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Menlo Park, CA 94025 (US).
    [Show full text]
  • Glaucoma Medical Treatment: Philosophy, Principles and Practice
    Glaucoma medical CLIVE MIGDAL treatment: philosophy, principles and practice Abstract assessment of these parameters. Indeed There have been numerous recent advances in compounds are under evaluation that affect the the management of glaucoma, not least the function of the optic nerve (via improved blood development of new drugs to help manage supply or improved neuronal cell physiology) raised intraocular pressure. In addition, the but may or may not lower lOP. It may even be concepts of improving blood flow to the optic possible in the future to therapeutically alter the nerve head and neuroprotection are currently human genome, genetically deliver provoking considerable interest. This article neuroprotective substances or aid regeneration considers the aims and philosophy of of the optic nerve axons. glaucoma drug therapy, summarises some of The main aim of glaucoma therapy must still the basic facts and principles of modem be the preservation of visual function. At the glaucoma medications, and suggests a same time, the therapy should not have adverse practical approach to the choice of therapy. side effects and should not affect the quality of life of the patient (by causing either side effects Key words Blood flow, Intraocular pressure, or inconvenience and disruption of daily Neuroprotection, Primary open angle glaucoma, Topical medications lifestyle). The cost of the therapy, both direct and indirect, must also be taken into consideration.s Currently, typical glaucoma management Philosophy consists of lowering the lOP to a satisfactory Primary open-angle glaucoma is a complex and safe target leve1.6 To determine the success disease for which a number of risk factors have of this treatment, the patient must be followed been identified, including intraocular pressure, long-term with routine assessment of lOP, discs age, race and family history.l,2 Due to our and fields to exclude progressive damage.
    [Show full text]
  • Comparison of the Efficacy and Safety of Fixed Combination
    Srp Arh Celok Lek. 2013 Jul-Aug;141(7-8):441-446 DOI: 10.2298/SARH1308441B ОРИГИНАЛНИ РАД / ORIGINAL ARTICLE UDC: 617.7-007.681-085 441 Comparison of the Efficacy and Safety of Fixed Combination Travoprost/Timolol and Dorzolamide/ Timolol in Patients with Primary Open-Angle Glaucoma and Ocular Hypertension Nikola Babić1,2, Veljko Andreić1, Aleksandar Miljković1,2, Desanka Grković1,2, Predrag Jovanović3 1Eye Clinic, Clinical Center of Vojvodina, Novi Sad, Serbia; 2Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia; 3Eye Clinic, Clinical Center, Niš, Serbia SUMMARY Introduction Combining two medications in one bottle may improve compliance by reducing the time required to administer drops and the frequency of the total number of medication bottles. Objective To compare the efficacy of reduced intraocular pressure (IOP) and safety of fixed combination travoprost 0.004%/timolol 0.5% vs. fixed combination dorzolamide 2%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Methods Prospective randomized clinical study included 60 patients divided into 2 groups. Follow-up was done at day 14 and 45 and month 3. IOP measurements were taken at each follow-up examination at 8 am, 10 am and 4 pm. Results Both fixed combinations reduced IOP significantly compared to initial values at all follow-ups (p<0.001). Mean pooled IOP at all visits and time points was slightly lower in the travoprost/timolol group compared with the dorzolamide/timolol group (16.13 mmHg vs. 16.15 mmHg). Mean IOP reduction from baseline ranged from -7.46 mmHg to -9.92 mmHg in the travoprost/timolol group and from -6.93 mmHg to -8.93 mmHg for the dorzolamide/timolol group.
    [Show full text]
  • Package Leaflet: Information for the Patient Dorzolamide/Timolol Olikla
    Package leaflet: Information for the patient Dorzolamide/Timolol Olikla 20 mg/ml + 5 mg/ml eye drops, solution dorzolamide/timolol Read all of this leaflet carefully before you start using this medicine because it contains important information for you. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects , talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Dorzolamide/Timolol Olikla is and what it is used for 2. What you need to know before you use Dorzolamide/Timolol Olikla 3. How to use Dorzolamide/Timolol Olikla 4. Possible side effects 5. How to store Dorzolamide/Timolol Olikla 6. Contents of the pack and other information 1. What Dorzolamide/Timolol Olikla is and what it is used for Dorzolamide/Timolol Olikla is a combination of two medicines: dorzolamide and timolol. Dorzolamide belongs to a group of medicines called “carbonic anhydrase inhibitors”. Timolol belongs to a group of medicines called “beta-blockers”. These medicines lower the pressure in the eye in different ways Dorzolamide/Timolol Olikla is prescribed to lower raised pressure within the eye in the treatment of glaucoma when beta-blocker eye drop medicine used alone is not adequate. 2. What you need to know before you use Dorzolamide/Timolol Olikla Do not use Dorzolamide/Timolol Olikla if you are allergic to dorzolamide hydrochloride, timolol maleate or any of the other ingredients of this medicine (listed in section 6).
    [Show full text]
  • Risk Management Plan Dorzolamide/Timolol Is Used To
    Risk Management Plan VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Dorzolamide/Timolol is used to reduce pressure in the eye in relatively common conditions known as open angle glaucoma or pseudoexfoliative glaucoma which result from a build-up of fluid. Around 2% of people older than 40 years of age have long-term open angle glaucoma, a figure which rises to almost 10% in people older than 75 years.1 Untreated open angle glaucoma leads to gradual vision loss. Hence, prevention or at least minimisation of ongoing damage is paramount to maintenance of vision. Pseudoexfoliative glaucoma is less common. 1 Risk Management Plan Risk factors for open-angle glaucoma include increased age, African ethnicity, family history and other eye disorders1 , for pseudoexfoliative glaucoma include sex (female gender), age (rarely seen before age 50) and Scandinavian origin2. VI.2.2 Summary of treatment benefits In clinical studies, the effect of the dorzolamide and timolol eye drops prescribed in combination to reduce eye pressure has been shown to be greater than when either substance is administered alone. The eye pressure lowering effect has been demonstrated when measured at various time points throughout the day and has been maintained during long-term administration. The effect was also similar in patients given dorzolamide-timolol in a fixed combination compared to a group that received treatment with separate drops of dorzolamide and timolol. The benefit of dorzolamide timolol fixed combination lies in the simplification of the dosing regimen by reducing the prescribed number of doses per day. It has been documented that less frequent dosing regimens results in better adherence to the drug dosage regimen by patients 3 Use of the fixed combination also decreases the load of preservatives (chemicals that discourage the growth of bacteria that may irritate eyes once the bottle has been opened) to which the patient’s eyes are exposed.
    [Show full text]
  • Dorzolamide/Timolol 20Mg/Ml + 5Mg/Ml Eye Drops, Solution
    Package leaflet: Information for the user Dorzolamide/Timolol 20mg/ml + 5mg/ml Eye Drops, Solution Read all of this leaflet carefully before Before surgery and anaesthesia (even at the you start using this medicine because it dentist), tell your doctor or dentist that you are contains important information for you. using Dorzolamide/Timolol eye drops, as this medicine may change effects of some medicines - Keep this leaflet. You may need to read it used during anaesthesia and there may be a again. sudden fall in blood pressure associated with the - If you have any further questions, ask your anaesthetic. doctor or pharmacist. - This medicine has been prescribed for you Children and adolescents only. Do not pass it on to others. It may harm There is limited experience with Dorzolamide/ them, even if their signs of illness are the Timolol eye drops in infants and children. same as yours. Use in elderly - If you get any side effects, talk to your doctor In studies with Dorzolamide/Timolol eye or pharmacist. This includes any possible side drops, the effects of Dorzolamide/Timolol eye effects not listed in this leaflet. See section 4. drops were similar in both elderly and younger - The full name of this medicine is patients. Dorzolamide/Timolol 20mg/ml + 5mg/ml Other medicines and Dorzolamide/ Eye Drops, Solution but within the leaflet it Timolol eye drops will be referred to as Dorzolamide/Timolol Dorzolamide/Timolol eye drops can affect or eye drops. be affected by other medicines you are using, including other eye drops for the treatment of What is in this leaflet: glaucoma.
    [Show full text]
  • Periorbital Dermatitis As a Side Effect of Topical Dorzolamide Y M Delaney, J F Salmon, F Mossa, B Gee, K Beehne, S Powell
    378 SCIENTIFIC CORRESPONDENCE Br J Ophthalmol: first published as 10.1136/bjo.86.4.378 on 1 April 2002. Downloaded from Periorbital dermatitis as a side effect of topical dorzolamide Y M Delaney, J F Salmon, F Mossa, B Gee, K Beehne, S Powell ............................................................................................................................. Br J Ophthalmol 2002;86:378–380 Aim: To report periorbital dermatitis as a late side effect of topical dorzolamide hydrochloride (Trusopt), a drug used to reduce intraocular pressure. Methods: A retrospective study of 14 patients who devel- oped periorbital dermatitis while using topical dorzola- mide hydrochloride was undertaken. Six patients underwent patch testing for sensitivity to Trusopt, dorzola- mide hydrochloride, and the preservative benzalkonium chloride. Results: The periorbital dermatitis occurred after a mean period of 20.4 weeks of commencing dorzolamide hydro- β chloride therapy. 13 patients had used preserved topical Figure 1 Case 14. Marked dermatitis of the left lower lid and blocker treatment for a mean period of 34.2 months with- periorbital area, which resolved on discontinuing topical out complication before the introduction of dorzolamide. In dorzolamide. eight (57.1%) the dermatitis resolved completely after dis- continuing dorzolamide but in six (42.9%) resolution of the dermatitis did not occur until the concomitant preserved β blocker was stopped and substituted with preservative free drops. Patch testing for sensitivity to Trusopt, dorzolamide hydrochloride, and benzalkonium chloride was negative. Conclusion: These findings suggest that dorzolamide can cause severe periorbital dermatitis. Although the dermatitis may resolve when dorzolamide is discontinued, this does http://bjo.bmj.com/ not always occur and in some patients all topical medication containing benzalkonium chloride needs to be stopped.
    [Show full text]
  • [Dorzolamide/Timolol] 20 Mg/Ml + 5 Mg/Ml Eye Drops, Solution
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT [Dorzolamide/Timolol] 20 mg/ml + 5 mg/ml eye drops, solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains 20 mg dorzolamide (as Dorzolamide hydrochloride) and 5 mg timolol (as timolol maleate). Excipient(s) with known effect Each ml of eye drops solution contains 0.075 mg benzalkonium chloride. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Eye drops, solution. Clear, slightly viscous, colourless aqueous solution. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications [Dorzolamide/Timolol] is indicated in the treatment of elevated intra-ocular pressure (IOP) in patients with open-angle glaucoma or pseudo-exfoliative glaucoma when topical beta-blocker monotherapy is not sufficient. 4.2 Posology and method of administration The dose is one drop of [Dorzolamide/Timolol] in the (conjunctival sac of the) affected eye(s) two times daily. When using nasolacrimal occlusion or closing the eyelids for 2 minutes, the systemic absorption is reduced. This may result in a decrease in systemic side effects and an increase in local activity. If another topical ophthalmic medicinal product is being used, the other agent should be administered at least ten minutes apart. Patients should be instructed to wash their hands before use and avoid allowing the tip of the dispensing container to contact the eye or surrounding structures. In order to secure correct dosage - the dropper tip should not be enlarged. Patients should also be instructed that ocular solutions, if handled improperly, can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.
    [Show full text]
  • Drug Class Review Ophthalmic Beta-Adrenergic Antagonists
    Drug Class Review Ophthalmic Beta-Adrenergic Antagonists 52:40.08 Beta-Adrenergic Blocking Agents Betaxolol (Betoptic®) Carteolol (Ocupress®) Levobunolol (Betagan®) Metipranolol (Optipranolol®) Timolol (Betimol®, Timoptic®, others) Timolol/Brimonidine (Combigan®) Timolol/Dorzolamide (Cosopt®; Cosopt PF®) Final Report November 2015 Review prepared by: Melissa Archer, PharmD, Clinical Pharmacist Carin Steinvoort, PharmD, Clinical Pharmacist Gary Oderda, PharmD, MPH, Professor University of Utah College of Pharmacy Copyright © 2015 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved. Table of Contents Executive Summary ......................................................................................................................... 3 Introduction .................................................................................................................................... 5 Table 1. Glaucoma Therapies ................................................................................................. 6 Table 2. Summary of Agents .................................................................................................. 7 Disease Overview ...................................................................................................................... 10 Table 3. Summary of Current Clinical Practice Guidelines .................................................. 11 Pharmacology ..............................................................................................................................
    [Show full text]
  • Drugs That May Be Used Based on Licensure Designation Page 1 of 7 Updated February 2021 by the Pennsylvania State Board of Optometry
    Drugs Which May Be Used Based on Licensure Designation Approved Drugs a.) Administration and prescription of pharmaceutical agents for therapeutic purposes. Optometrists who are certified to prescribe and administer pharmaceutical agents for therapeutic purposes under section 4.1 of the Optometric Practice and Licensure Act (63 P. S. § 244.4a), may prescribe and administer the drugs listed in subsections (c)(1) – (11) below in their practice of optometry. See also 49 Pa. Code § 23.202 for the application procedure for optometrists to administer and prescribe pharmaceutical agents for therapeutic purposes. b.) Administration and prescription of pharmaceutical agents to treat glaucoma. Optometrists who are certified to prescribe and administer pharmaceutical agents to treat glaucoma under section 4.2 of the Optometric Practice and Licensure Act (63 P.S. § 244.4b), may prescribe and administer the drugs listed in subsection (c)(12) below in their practice of optometry. See also 49 Pa. Code § 23.205 for the application procedure for optometrists to administer and prescribe pharmaceutical agents to treat glaucoma. c.) DEA registration reminder. Licensees who hold, or plan to obtain, a DEA registration are reminded to review and comply with PDMP standards. d.) Allowable pharmaceutical products. Optometrists may prescribe and administer the following pharmaceutical products or the A-rated generic therapeutically equivalent drug: (1) Topical Anesthetics (i) benoxinate (ii) lidocaine (iii) proparacaine (iv) tetracaine (2) Topical Ocular Lubricants
    [Show full text]
  • Estonian Statistics on Medicines 2013 1/44
    Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
    [Show full text]
  • Dorzolamide 20 Mg/Ml and Timolol 5 Mg/Ml Eye Drops, Solution
    Package leaflet: Information for the user Dorzolamide 20 mg/ml and Timolol 5 mg/ml Eye Drops, Solution (Dorzolamide hydrochloride / Timolol maleate) Read all of this leaflet carefully before you start using this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. - Your medicine, Dorzolamide 20 mg/ml and Timolol 5 mg/ml Eye Drops, Solution will be referred to as Dorzolamide/Timolol in this leaflet. What is in this leaflet 1. What Dorzolamide/Timolol is and what it is used for 2. What you need to know before you use Dorzolamide/Timolol 3. How to use Dorzolamide/Timolol 4. Possible side effects 5. How to store Dorzolamide/Timolol 6. Contents of the pack and other information 1. What dorzolamide/timolol is and what it is used for These eye drops contain two medicines: dorzolamide and timolol. • Dorzolamide belongs to a group of medicines called "carbonic anhydrase inhibitors". • Timolol belongs to a group of medicines called "beta blockers". These medicines lower the pressure in the eye in different ways. Dorzolamide/Timolol is prescribed to lower raised pressure in the eye in the treatment of glaucoma when beta-blocker eye drop medicine used alone is not adequate.
    [Show full text]